• Home
  • News
  • Calendar
  • About DF/HCC
  • Membership
  • Visitor Center

Susana M. Campos, MD


  • Campos SM, Brady WE, Moxley KM, O'Cearbhaill RE, Lee PS, Disilvestro PA, Rotmensch J, Rose PG, Thaker PH, O'Malley DM, Hanjani P, Zuna RE, Hensley ML.A phase II evaluation of pazopanib in the treatment of recurrent or persistent carcinosarcoma of the uterus: A Gynecologic Oncology Group study.Gynecol Oncol. 2014 Mar 1.
  • Koh WJ, Greer BE, Abu-Rustum NR, Apte SM, Campos SM, Chan J, Cho KR, Cohn D, Crispens MA, Dupont N, Eifel PJ, Fader AN, Fisher CM, Gaffney DK, George S, Han E, Huh WK, Lurain JR, Martin L, Mutch D, Remmenga SW, Reynolds RK, Small W, Teng N, Tillmanns T, Valea FA, McMillian N, Hughes M.Uterine neoplasms, version 1.2014.J Natl Compr Canc Netw. 2014 Feb;12(2):248-80.
  • Viswanathan AN, Lee H, Berkowitz R, Berlin S, Campos S, Feltmate C, Horowitz N, Muto M, Sadow CA, Matulonis U.A prospective feasibility study of radiation and concurrent bevacizumab for recurrent endometrial cancer.Gynecol Oncol. 2014 Jan;132(1):55-60.
  • Dizon DS, Ambrosio AJ, Feltmate C, Wright AA, Campos SM, Viswanathan A, .Pushing the bar in treatment of cervical cancer: what can comprehensive cancer centers do on their own?.Gynecol Oncol. 2013 Nov;131(2):464-6.
  • Rauh-Hain JA, Nitschmann CC, Worley MJ, Bradford LS, Berkowitz RS, Schorge JO, Campos SM, Del Carmen MG, Horowitz NS.Platinum resistance after neoadjuvant chemotherapy compared to primary surgery in patients with advanced epithelial ovarian carcinoma.Gynecol Oncol. 2013 Apr;129(1):63-8.
  • Koh WJ, Greer BE, Abu-Rustum NR, Apte SM, Campos SM, Chan J, Cho KR, Cohn D, Crispens MA, DuPont N, Eifel PJ, Gaffney DK, Giuntoli RL, Han E, Huh WK, Lurain JR, Martin L, Morgan MA, Mutch D, Remmenga SW, Reynolds RK, Small W, Teng N, Tillmanns T, Valea FA, McMillian NR, Hughes M.Cervical cancer.J Natl Compr Canc Netw. 2013 Mar 1;11(3):320-43.
  • Campos SM, Penson RT, Matulonis U, Horowitz NS, Whalen C, Pereira L, Tyburski K, Roche M, Szymonifka J, Berlin S.A phase II trial of Sunitinib malate in recurrent and refractory ovarian, fallopian tube and peritoneal carcinoma.Gynecol Oncol. 2012 Aug 9.
  • Campos SM, Berlin S, Matulonis UA, Muto MG, Pereira L, Mosquera MM, Horowitz N.Young women diagnosed with early-stage ovarian cancer or borderline malignancy of the ovary: a focus on fertility and sexual function.J Psychosoc Oncol. 2012;30(4):387-401.
  • Matulonis UA, Pereira L, Liu J, Lee H, Lee J, Whalen C, Campos S, Atkinson T, Hill M, Berlin S.Sequential bevacizumab and oral cyclophosphamide for recurrent ovarian cancer.Gynecol Oncol. 2012 Jul;126(1):41-6.
  • Greer BE, Koh WJ, Abu-Rustum NR, Apte SM, Campos SM, Chan J, Cho KR, Copeland L, Crispens MA, Dupont N, Eifel PJ, Gaffney DK, Huh WK, Kapp DS, Lurain JR, Martin L, Morgan MA, Morgan RJ, Mutch D, Remmenga SW, Reynolds RK, Small W, Teng N, Valea FA.Cervical cancer.J Natl Compr Canc Netw. 2010 Dec;8(12):1388-416.
  • Campos SM, Berlin ST, Parker LM, Chen WY, Bunnell CA, Atkinson T, Lee J, Matulonis U, Hirsch MS, Harris L, Krasner CN.Phase I trial of liposomal doxorubicin and ZD1839 in patients with refractory gynecological malignancies or metastatic breast cancer.Int J Clin Oncol. 2010 Aug;15(4):390-8.
  • Campos SM, Ghosh S.A current review of targeted therapeutics for ovarian cancer.J Oncol. 2010;2010:149362.
  • Penson RT, Dizon DS, Cannistra SA, Roche MR, Krasner CN, Berlin ST, Horowitz NS, Disilvestro PA, Matulonis UA, Lee H, King MA, Campos SM.Phase II study of carboplatin, paclitaxel, and bevacizumab with maintenance bevacizumab as first-line chemotherapy for advanced mullerian tumors.J Clin Oncol. 2010 Jan 1;28(1):154-9.
  • Matulonis UA, Berlin S, Ivy P, Tyburski K, Krasner C, Zarwan C, Berkenblit A, Campos S, Horowitz N, Cannistra SA, Lee H, Lee J, Roche M, Hill M, Whalen C, Sullivan L, Tran C, Humphreys BD, Penson RT.Cediranib, an oral inhibitor of vascular endothelial growth factor receptor kinases, is an active drug in recurrent epithelial ovarian, fallopian tube, and peritoneal cancer.J Clin Oncol. 2009 Nov 20;27(33):5601-6.
  • Mirabeau-Beale KL,Kornblith AB,Penson RT,Lee H,Goodman A,Campos SM,Duska L,Pereira L,Bryan J,Matulonis UA.Comparison of the quality of life of early and advanced stage ovarian cancer survivors.Gynecol Oncol. 2009 Aug;114(2):353-9.
  • Greer BE,Koh WJ,Abu-Rustum N,Bookman MA,Bristow RE,Campos SM,Cho KR,Copeland L,Crispens MA,Eifel PJ,Huh WK,Jaggernauth W,Kapp DS,Kavanagh JJ,Lurain JR 3rd,Morgan M,Morgan RJ,Powell CB,Remmenga SW,Reynolds RK,Alvarez Secord A,Small W Jr,Teng N.NCCN Clinical Practice Guidelines in Oncology: Uterine Neoplasms.J Natl Compr Canc Netw. 2009 May;7(5):498-531. Review.
  • Campos SM,Guastalla JP,Subar M,Abreu P,Winer EP,Cameron DA.A comparative study of exemestane versus anastrozole in patients with postmenopausal breast cancer with visceral metastases.Clin Breast Cancer. 2009 Feb;9(1):39-44.
  • Burstein HJ,Chen YH,Parker LM,Savoie J,Younger J,Kuter I,Ryan PD,Garber JE,Chen H,Campos SM,Shulman LN,Harris LN,Gelman R,Winer EP.VEGF as a marker for outcome among advanced breast cancer patients receiving anti-VEGF therapy with bevacizumab and vinorelbine chemotherapy.Clin Cancer Res. 2008 Dec 1;14(23):7871-7.
  • Matulonis UA,Horowitz NS,Campos SM,Lee H,Lee J,Krasner CN,Berlin S,Roche MR,Duska LR,Pereira L,Kendall D,Penson RT.Phase II study of carboplatin and pemetrexed for the treatment of platinum-sensitive recurrent ovarian cancer.J Clin Oncol. 2008 Dec 10;26(35):5761-6.
  • Molina FD, Bertollo EM, Assis CM, Falleiros LR Jr, Campos SG, Maniglia JV, Taboga SR.Apoptosis in tongue squamous cell carcinoma and its correlation with clinically occult cervical metastasis.Micron. 2008 Oct;39(7):910-4.
  • Castells MC,Tennant NM,Sloane DE,Hsu FI,Barrett NA,Hong DI,Laidlaw TM,Legere HJ,Nallamshetty SN,Palis RI,Rao JJ,Berlin ST,Campos SM,Matulonis UA.Hypersensitivity reactions to chemotherapy: outcomes and safety of rapid desensitization in 413 cases.J Allergy Clin Immunol. 2008 Sep;122(3):574-80.
  • Greer BE, Koh WJ, Abu-Rustum N, Bookman MA, Bristow RE, Campos S, Cho KR, Copeland L, Eifel P, Huh WK, Jaggernauth W, Kapp DS, Kavanagh J, Lipscomb GH, Lurain JR 3rd, Morgan M, Morgan RJ Jr, Powell CB, Remmenga SW, Reynolds RK, Secord AA, Small W Jr, Teng N, National Comprehensive Cancer Network.Cervical cancer.J Natl Compr Canc Netw. 2008 Jan;6(1):14-36.
  • Partridge EE, Abu-Rustum N, Campos S, Fahey PJ, Greer BE, Lele SM, Lieberman RW, Lipscomb GH, Morgan M, Nava ME, Reynolds RK, Singh DK, Smith-McCune K, Teng N, Trimble CL, Valea F, Wilczynski S, National Comprehensive Cancer Network.Cervical cancer screening.J Natl Compr Canc Netw. 2008 Jan;6(1):58-82.
  • Campos SG, Zanetoni C, Scarano WR, Vilamaior PS, Taboga SR.Age-related histopathological lesions in the Mongolian gerbil ventral prostate as a good model for studies of spontaneous hormone-related disorders.Int J Exp Pathol. 2008 Feb;89(1):13-24.
  • Matulonis UA, Campos S, Krasner CN, Duska LR, Penson RT, Falke R, Roche M, Smith LM, Lee H, Seiden MV, ,.Three sequential chemotherapy doublets for the treatment of newly diagnosed advanced müllerian malignancies: The modified triple doublet regimen.Gynecol Oncol. 2006 Nov;103(2):575-80.
  • Matulonis UA, Campos S, Duska L, Krasner CN, Atkinson T, Penson RT, Seiden MV, Verrill C, Fuller AF, Goodman A,.Phase I/II dose finding study of combination cisplatin and gemcitabine in patients with recurrent cervix cancer.Gynecol Oncol. 2006 Oct;103(1):160-4.
  • Campos S, Seiden MV, Oza A, Plante M, Potkul R, Hamid O, Lenehan P, Kaldjian E, Jordan C, Hirte HA.A Phase II, randomized, open-label, single agent study of CI-1033 administered at two dose levels in ovarian cancer patients who failed prior platinum based therapy.Proceedings of the American Association of Clinical Oncology.:In press.
  • Penson RT, Campos SM, Seiden MV, Krasner C, Fuller AF, Goodman A, Roche M, Willman A, Muzikansky A, Matulonis UA,.A phase II study of fixed dose rate gemcitabine in patients with relapsed müllerian tumors.Int J Gynecol Cancer. 2005 Nov-Dec;15(6):1035-41.
  • Campos SM, Duh MS, Lefebvre P, Rosberg J.Benefits associated with an early hemoglobin response to epoetin alfa therapy in the treatment of chemotherapy-related anemia.J Natl Compr Canc Netw. 2005 Nov;3(6):807-16.
  • Campos S, Hamid O, Seiden MV, Oza A, Plante M, Potkul RK, Lenehan PF, Kaldjian EP, Varterasian ML, Jordan C, Charbonneau C, Hirte H.Multicenter, randomized phase II trial of oral CI-1033 for previously treated advanced ovarian cancer.J Clin Oncol. 2005 Aug 20;23(24):5597-604.
  • Penson RT, Seiden MV, Matulonis UA, Appleman LJ, Fuller AF, Goodman A, Campos SM, Clark JW, Roche M, Eder JP.A phase I clinical trial of continual alternating etoposide and topotecan in refractory solid tumours.Br J Cancer. 2005 Jul 11;93(1):54-9.
  • Gribben JG, Ryan DP, Boyajian R, Urban RG, Hedley ML, Beach K, Nealon P, Matulonis U, Campos S, Gilligan TD, Richardson PG, Marshall B, Neuberg D, Nadler LM.Unexpected association between induction of immunity to the universal tumor antigen CYP1B1 and response to next therapy.Clin Cancer Res. 2005 Jun 15;11(12):4430-6.
  • Campos SM.Evolving treatment approaches for early breast cancer.Breast Cancer Res Treat. 2005;89 Suppl 1:S1-7.
  • Duska LR, Berkowitz R, Matulonis U, Muto M, Goodman A, McIntyre JF, Klein A, Atkinson T, Seiden MV, Campos S.A pilot trial of TAC (paclitaxel, doxorubicin, and carboplatin) chemotherapy with filgastrim (r-metHuG-CSF) support followed by radiotherapy in patients with "high-risk" endometrial cancer.Gynecol Oncol. 2005 Jan;96(1):198-203.
  • Thigpen JT, Aghajanian CA, Alberts DS, Campos SM, Gordon AN, Markman M, McMeekin DS, Monk BJ, Rose PG.Role of pegylated liposomal doxorubicin in ovarian cancer.Gynecol Oncol. 2005 Jan;96(1):10-8.
  • Penson RT, Seiden MV, Goodman A, Fuller AF, Berkowitz RS, Matulonis UA, Krasner C, Lee H, Atkinson T, Campos SM,.Phase I trial of escalating doses of topotecan in combination with a fixed dose of pegylated liposomal doxorubicin in women with müllerian malignancies.Gynecol Oncol. 2004 Jun;93(3):702-7.
  • Seiden MV, Muggia F, Astrow A, Matulonis U, Campos S, Roche M, Sivret J, Rusk J, Barrett E.A phase II study of liposomal lurtotecan (OSI-211) in patients with topotecan resistant ovarian cancer.Gynecol Oncol. 2004 Apr;93(1):229-32.
  • del Carmen MG, Fuller AF, Matulonis U, Horick NK, Goodman A, Duska LR, Penson R, Campos S, Roche M, Seiden MV.Phase II trial of anastrozole in women with asymptomatic müllerian cancer.Gynecol Oncol. 2003 Dec;91(3):596-602.
  • Matulonis U, Campos S, Duska L, Fuller A, Berkowitz R, Gore S, Roche M, Colella T, Lee H, Seiden MV, ,.A phase II trial of three sequential doublets for the treatment of advanced müllerian malignancies.Gynecol Oncol. 2003 Nov;91(2):293-8.
  • Campos SM, Matulonis UA, Penson RT, Lee H, Berkowitz RS, Duska LR, Fuller AF, Wilson KS, Puchalski TA, Supko JG, Seiden MV.Phase II study of liposomal doxorubicin and weekly paclitaxel for recurrent Müllerian tumors.Gynecol Oncol. 2003 Sep;90(3):610-8.
  • Burstein HJ, Harris LN, Marcom PK, Lambert-Falls R, Havlin K, Overmoyer B, Friedlander RJ, Gargiulo J, Strenger R, Vogel CL, Ryan PD, Ellis MJ, Nunes RA, Bunnell CA, Campos SM, Hallor M, Gelman R, Winer EP.Trastuzumab and vinorelbine as first-line therapy for HER2-overexpressing metastatic breast cancer: multicenter phase II trial with clinical outcomes, analysis of serum tumor markers as predictive factors, and cardiac surveillance algorithm.J Clin Oncol. 2003 Aug 1;21(15):2889-95.
  • Seiden MV, Swenerton KD, Matulonis U, Campos S, Rose P, Batist G, Ette E, Garg V, Fuller A, Harding MW, Charpentier D.A phase II study of the MDR inhibitor biricodar (INCEL, VX-710) and paclitaxel in women with advanced ovarian cancer refractory to paclitaxel therapy.Gynecol Oncol. 2002 Sep;86(3):302-10.
  • Vasey PA, Shulman LN, Campos S, Davis J, Gore M, Johnston S, Kirn DH, O'Neill V, Siddiqui N, Seiden MV, Kaye SB.Phase I trial of intraperitoneal injection of the E1B-55-kd-gene-deleted adenovirus ONYX-015 (dl1520) given on days 1 through 5 every 3 weeks in patients with recurrent/refractory epithelial ovarian cancer.J Clin Oncol. 2002 Mar 15;20(6):1562-9.
  • Penson RT, Supko JG, Seiden MV, Fuller AF, Berkowitz RS, Goodman A, Campos SM, MacNeill KM, Cook S, Matulonis UA.A Phase I-II study of 96-hour infusional topotecan and paclitaxel for patients with recurrent Müllerian tumors.Cancer. 2001 Sep 1;92(5):1156-67.
  • Burstein HJ, Kuter I, Campos SM, Gelman RS, Tribou L, Parker LM, Manola J, Younger J, Matulonis U, Bunnell CA, Partridge AH, Richardson PG, Clarke K, Shulman LN, Winer EP.Clinical activity of trastuzumab and vinorelbine in women with HER2-overexpressing metastatic breast cancer.J Clin Oncol. 2001 May 15;19(10):2722-30.
  • Campos SM, Penson RT, Mays AR, Berkowitz RS, Fuller AF, Goodman A, Matulonis UA, Muzikansky A, Seiden MV.The clinical utility of liposomal doxorubicin in recurrent ovarian cancer.Gynecol Oncol. 2001 May;81(2):206-12.